|
|
Sold Out
Book Categories |
Section: I BIOLOGY;
1. Esophageal Embryology and Congenital Disorders 2. Esophageal Anatomy;
3. The Biology of Epithelial Esophageal Cancer;
4. The Biology of Mesenchymal Esophageal Tumors;
5. Barrett's Esophagus: Epidemiology and Pathogenesis;
6. Barrett's Esophagus: Molecular Biology;
7. Barrett's Esophagus: Preclinical Models for Investigation;
8. Barrett's Esophagus: Screening and Surveillance;
9. Barrett's Esophagus: Models for Cost-Effective Screening and Surveillance;
10. Barrett's Esophagus: Chemoprevention;
11. Epidemiology of Esophageal Cancer: Molecular;
12. Epidemiology and Risk of Esophageal Cancer: Clinical;
13. Pathology of Barrett's Esophagus and Esophageal Neoplasms;
14. The Link Between Esophageal Cancer and Morbid Obesity;
15. The Relationship Between ,
16. Ethnic Disparities in Cancer of the Esophagus; Section II: IMAGING AND STAGING 17. State of the Art in Esophageal Imaging: Endoscopic Technology and Evaluation of Esophageal Mucosa;
18. Esophageal Imaging: Anatomic;
19. Esophageal Imaging: Functional - PET;
20. Esophageal Imaging: Functional - MRI;
21. Esophageal Cancer Staging -Clinical;
22. Esophageal Cancer Staging - EMR;
23. Esophageal Cancer Staging - Surgical;
24. Restaging after Neoadjuvant Therapy;
25. Revisions in the Staging System for Esophageal Cancer; Section III: PRINCIPLES OF THERAPY;
26. Rationale for Tailored Treatment;
27. Principles of Multimodality Therapy;
28. Principles of Chemotherapy;
29. Principles of Systemic Therapy: Targeted Therapy;
30. Principles of Radiation Therapy;
31. Principles of Surgical Therapy;
32. The Relationship Between Volume and Outcome in the Treatment of Esophageal Cancer; Section IV: TUMOR TYPES;
33. Benign: Lipoma;
34. Benign: Fibrovascular Polyp;
35. Benign: Fibrolipoma;
36. Benign: Hemangioma;
37. Benign: Granular Cell Tumors;
38. Benign: Neurofibroma;
39. Benign: Leiomyoma;
40. Benign: Hamartoma;
41. Benign: Congenital - Duplication Cysts;
42. Benign: Congenital - Bronchogenic Cysts;
43. Malignant: Squamous Cell Carcinoma and Variants;
44. Malignant: Esophageal Adenocarcinoma and Variants;
45. Malignant: Esophageal Adenocarcinoma of the Cardia and Proximal Stomach;
46. Malignant: Mesenchymal Tumors;
47. Malignant: Lymphoma;
48. Malignant: Metastatic; Section V: THERAPY49. Multidisciplinary Care Team: Structure and Format;
50. Informed Consent in the Esophageal Cancer Patient;
51. Review and Synthesis of Clinical Trials in Esophageal Cancer;
52. Pretreatment Planning in Radiation Therapy of the Esophagus;
53. Adjuvant (Postoperative) Therapy;
54. Neoadjuvant Therapy;
55. Definitive Radiochemotherapy;
56. Endoscopic Therapies for Barrett's Esophagus;
57. Endoscopic Therapy for Superficial Cancerr;
58. Therapy for Advanced Locoregional Cancer;
59. Treatment Options for Locally Recurrent Esophageal Cancer;
60. Preoperative Immunonutrition;
61. Surgery Techniques: Management of Benign Esophageal Tumors;
62. Surgery Techniques: Patient Preparation and Surgical Approach in Cancer Treatment;
63. Surgery Techniques: Anesthesia in the Esophageal Cancer Patient;
64. Surgery Techniques: Anastomotic Technique and Selection of Location;
65. Surgery Techniques: Conduit Preparation and Route of Reconstruction;
66. Surgery Techniques: Vagal-Sparing Esophagectomy;
67. Surgery Techniques: Minimally Invasive Esophagectomy;
68. Surgery Techniques: Ivor-Lewis Esophagectomy;
69. Surgery Techniques: Transhiatal Esophagectomy without Thoracotomy;
70. Surgery Techniques: Three-Field Esophagectomy;
71. Surgery Techniques: En Bloc Esophagectomy;
72. Surgery Techniques: Left Transthoracic and Thoracoabdominal Esophagectomy;
73. Surgery Techniques: Resection of Cancer Involving the Cervicothoracic Esophagus;
74. Surgery Techniques: Transhiatally Extended Total Gastrectomy;
75. Surgery Techniques: Salvage Esophagectomy;
76. Surgery Techniques: Postoperative Care;
77. Managing the Complications of Multimodality Therapy;
78. Postoperative Care and Management of the Complications of Surgical Therapy;
79. Quality of Life after Esophagectomy;
80. Proper Follow-up after Definitive Therapy; Section VI: PALLIATION;
81. Guidelines for Palliative Care: Hospital and Hospice;
82. Care of the Psychosocial Needs of the Patient and Family;
83. Objective Scoring Systems in the Palliative Setting;
84. Guidelines for Pain Control in the Esophageal Cancer Patient;
85. Endoscopic Palliation of Dysphagia: Photodynamic Therapy;
86. Endoscopic Palliation of Dysphagia: Stenting;
87. Endoscopic Palliation of Dysphagia: Laser;
88. Endoscopic Palliation of Dysphagia: Brachytherapy;
89. Surgical Palliation: Current Role;
90. Perforated Esophageal Cancer;
91. Radiation; Section VII: FUTURE DIRECTIONS;
2. Molecular Outcome Prediction; Index
| Price | Condition | Delivery | Seller | Action |
| $201.87 | Digital |
| WonderClub |
Ken Ballasy
reviewed Esophageal Cancer: Principles and Practice on February 15, 2013
Esophageal Cancer
I still can't decide where I fall: while it seems pretty clear exploitation is what's taking place, is it preferable to allow it to proceed given the paternalistic nature of disallowing it and yes, the benefits it can lead to or should it be regulated (resolutioned) against due to the precedent of immorality it sets? Three arguments resonated with me, although one is a daydream.
1) "We should not confuse our moral worries about the objective circumstances in which people find themselves with worries about their capacity or right to make decisions about their lives within those circumstances." (Wertheimer)
2) "The only time we should be conducting clinical research trials among impoverished communities that offer less than the world's best treatment in the control arm is when doing so is needed to help those in similar health circumstances (and not, say, because using this population provides an especially cheap way to collect clean data for those who do not suffer the 'useful' deprivation)." (Carse & Little)
3) A la Kant, "We need to show humility in our condemnations of those who exploit the impoverished, as it is our indifference to the true needs of the poor that sows much of the ground of exploitation. We must also exercise caution when legislating against exploitation, for the perverse reality is that the best prospect some persons currently have for improving their lives is to submit to exploitative exchanges. While our indignation at those who exploit the poor is certainly warranted, it is not until the day arrives that our indignation is accompanied by shame that we can hope for real progress." (Siegel)
Login|Complaints|Blog|Games|Digital Media|Souls|Obituary|Contact Us|FAQ
CAN'T FIND WHAT YOU'RE LOOKING FOR? CLICK HERE!!! X
You must be logged in to add to WishlistX
This item is in your Wish List
X
This item is in your Collection
Esophageal Cancer: Principles and Practice
X
This Item is in Your Inventory
Esophageal Cancer: Principles and Practice
X
You must be logged in to review the productsX
X
X
Add Esophageal Cancer: Principles and Practice, Gastroesophageal cancers are the most common form of cancer incidents, and the second most common cause of death among cancer patients. In 2000, it was estimated that over one million new cases of gastroesophageal cancers were diagnosed worldwide, and ove, Esophageal Cancer: Principles and Practice to the inventory that you are selling on WonderClubX
X
Add Esophageal Cancer: Principles and Practice, Gastroesophageal cancers are the most common form of cancer incidents, and the second most common cause of death among cancer patients. In 2000, it was estimated that over one million new cases of gastroesophageal cancers were diagnosed worldwide, and ove, Esophageal Cancer: Principles and Practice to your collection on WonderClub |
